KR101014891B1 - 신호 펩타이드 없이 박테리아로부터 항체의 분비 - Google Patents

신호 펩타이드 없이 박테리아로부터 항체의 분비 Download PDF

Info

Publication number
KR101014891B1
KR101014891B1 KR1020087004346A KR20087004346A KR101014891B1 KR 101014891 B1 KR101014891 B1 KR 101014891B1 KR 1020087004346 A KR1020087004346 A KR 1020087004346A KR 20087004346 A KR20087004346 A KR 20087004346A KR 101014891 B1 KR101014891 B1 KR 101014891B1
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
leu
pro
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087004346A
Other languages
English (en)
Korean (ko)
Other versions
KR20080031452A (ko
Inventor
게오프레이 야란톤
크리스토퍼 알. 베빙톤
Original Assignee
칼로바이오스 파마슈티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼로바이오스 파마슈티컬스, 아이엔씨. filed Critical 칼로바이오스 파마슈티컬스, 아이엔씨.
Publication of KR20080031452A publication Critical patent/KR20080031452A/ko
Application granted granted Critical
Publication of KR101014891B1 publication Critical patent/KR101014891B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020087004346A 2005-07-22 2006-07-07 신호 펩타이드 없이 박테리아로부터 항체의 분비 Expired - Fee Related KR101014891B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70190205P 2005-07-22 2005-07-22
US60/701,902 2005-07-22
US11/273,906 2005-11-14
US11/273,906 US8211648B2 (en) 2005-07-22 2005-11-14 Secretion of antibodies without signal peptides from bacteria

Publications (2)

Publication Number Publication Date
KR20080031452A KR20080031452A (ko) 2008-04-08
KR101014891B1 true KR101014891B1 (ko) 2011-02-15

Family

ID=37679517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087004346A Expired - Fee Related KR101014891B1 (ko) 2005-07-22 2006-07-07 신호 펩타이드 없이 박테리아로부터 항체의 분비

Country Status (11)

Country Link
US (2) US8211648B2 (enExample)
EP (1) EP1907610B1 (enExample)
JP (1) JP5087541B2 (enExample)
KR (1) KR101014891B1 (enExample)
CN (1) CN101568647B (enExample)
AU (1) AU2006276823B2 (enExample)
CA (1) CA2615776C (enExample)
IL (1) IL188889A (enExample)
NZ (1) NZ565126A (enExample)
SG (1) SG177895A1 (enExample)
WO (1) WO2007018853A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102037016B (zh) 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 针对粒细胞巨噬细胞集落刺激因子的抗体
WO2010091189A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20140006022A (ko) 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
WO2012133119A1 (ja) * 2011-03-28 2012-10-04 長瀬産業株式会社 フェリチンの製造方法
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
WO2014116051A1 (ko) * 2013-01-24 2014-07-31 스크립스코리아 항체연구원 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법
US10328149B2 (en) * 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
IL302725A (en) * 2016-01-13 2023-07-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843685A (en) * 1988-09-06 1998-12-01 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0967277A3 (en) 1988-09-06 2003-10-15 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0404003A3 (en) 1989-06-19 1991-10-16 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
JPH07289267A (ja) * 1994-04-25 1995-11-07 Oriental Yeast Co Ltd 発現増強方法
JPH09313191A (ja) 1996-03-28 1997-12-09 Mitsui Petrochem Ind Ltd 蛋白質の分泌生産法
US5824502A (en) * 1996-03-28 1998-10-20 Mitsui Chemicals, Inc. Method for secretory production of protein
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
DE10325026B4 (de) 2003-06-02 2013-04-18 Genencor International,Inc. Bakterien mit erhöhter Proteinsekretion, Nukleotidsequenzen codierend für ein SecA Protein mit erhöhter Proteinsekretion sowie Verfahren zur Produktion von Proteinen
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
JP2007502991A (ja) * 2003-08-20 2007-02-15 バイオサイト インコーポレイテッド 生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843685A (en) * 1988-09-06 1998-12-01 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EMBO J. Vol.12, pp.879-888, 1993*

Also Published As

Publication number Publication date
AU2006276823A1 (en) 2007-02-15
IL188889A (en) 2014-09-30
KR20080031452A (ko) 2008-04-08
AU2006276823B2 (en) 2010-04-22
IL188889A0 (en) 2008-04-13
WO2007018853A2 (en) 2007-02-15
CA2615776C (en) 2014-05-13
WO2007018853A3 (en) 2009-04-16
US20070020685A1 (en) 2007-01-25
US9127046B2 (en) 2015-09-08
CA2615776A1 (en) 2007-02-15
EP1907610A4 (en) 2009-12-23
CN101568647A (zh) 2009-10-28
JP2009510998A (ja) 2009-03-19
SG177895A1 (en) 2012-02-28
JP5087541B2 (ja) 2012-12-05
HK1113393A1 (en) 2008-10-03
NZ565126A (en) 2011-03-31
US20120309055A1 (en) 2012-12-06
US8211648B2 (en) 2012-07-03
CN101568647B (zh) 2012-10-03
EP1907610B1 (en) 2013-09-11
EP1907610A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
US9127046B2 (en) Secretion of antibodies without signal peptides from bacteria
AU2011215685B2 (en) Methods for identifying and isolating cells expressing a polypeptide
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
Pardon et al. A general protocol for the generation of Nanobodies for structural biology
EP2102239B1 (en) Improved immunoglobulin libraries
US7829684B2 (en) Methods for producing soluble membrane-spanning proteins
EA031449B1 (ru) Бактериальный штамм-акцептор, экспрессирующий рекомбинантный dsbc
US9109223B2 (en) Methods for generating and screening fusion protein libraries and uses thereof
Venturi et al. Monoclonal antibodies for the structural analysis of the Na+/H+ antiporter NhaA from Escherichia coli
HK1113393B (en) Secretion of antibodies without signal peptides from bacteria
CN119023975A (zh) 一种测定肉毒毒素活性或snap25的方法、检测产品及抗体
Deen Isolation of Human Endoplasmic Reticulum Antibodies Using Phage Display Technology
HK1178942B (en) Methods for identifying and isolating cells expressing a polypeptide

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20131128

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20141113

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160209

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160209

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000